134150-77-9Relevant academic research and scientific papers
TARGETING COMPOUNDS
-
Paragraph 0226; 0227, (2019/07/19)
The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
ORGANIC PHOSPHORUS COMPOUNDS 92. SYNTHESIS AND PROPERTIES OF AZETIDINE-3-PHOSPHONIC- AND 3-PHOSPHONOUS ACID
Diel, Peter J.,Maier, Ludwig
, p. 1 - 4 (2007/10/02)
Azetidine-3-phosphonic acid, 4a, and azetidine-3-phosphonous acid, 4b, have been prepared by the interaction of 1-benzhydryl-3-methanesulfonato-azetidine with sodium phosphite or sodium O-ethyl-diethoxymethylphosphonite, followed by catalytic debenzhydrylation with H2 and hydrolysis.Neither acid shows biological activity.
